Carrié C, Bardonneau G, Petit L, et al. - In this retrospective analysis of 244 patients who were critically ill and received treatment for wild-type AmpC-producing Enterobacterales pulmonary infections over a 4-year period, researchers compared third-generation cephalosporins (3GCs) vs piperacillin-tazobactam (PTZ) in terms of the rate of therapeutic failure. They found that therapeutic failure was faced by 56 (23%) patients. In the non-adjusted cohort, a significantly higher rate of therapeutic failure and emergence of resistance was noted in the 3GCs group. Higher rates of therapeutic failure were observed in relation to the use of 3GCs in the propensity score-matched population. No increased rate of emergence of resistance was noted in relation to the secondary de-escalation to 3GCs following 48 h of PTZ as a first-line antibiotic treatment. The recommendation for avoiding 3GCs as first-line antibiotic treatment in wild-type AmpC-generating Enterobacterales pulmonary infections was corroborated in this study.